Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Phys Vivasneurological

Phys Vivas · neurological

Neurocutaneous Syndromes — Viva Defence

DCE viva defence for Neurocutaneous Syndromes.

On this page & tools

Target exams

FRACP DCEMRCP PACES

Target exams

FRACP DCEMRCP PACES
Prompt
DCE viva defence for Neurocutaneous Syndromes.

Neurocutaneous Syndromes Viva

Long Case Viva Defence

Opening statement

"This patient presents with a problem best framed as Neurocutaneous Syndromes. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Short case

Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]

References

  1. [1]Zhang S, Yang G Neurofibromin in bone disease: Mechanisms and therapeutic implications (Review) Int J Mol Med, 2026.PMID 42464674
  2. [2]Calonge Q, Hanin A, Dade M, Bailly L, et al. Epilepsy and disability in adults with tuberous sclerosis complex: a 16-year retrospective analysis J Neurol, 2026.PMID 42458074
  3. [3]Zeppieri M, D'Esposito F, Gagliano C, Battista M, et al. Looking at Optic Nerve Sheath Meningiomas Through Genetics-From Clinic to Bench and Back Again Front Biosci (Schol Ed), 2026.PMID 42411653
  4. [4]Erdem S, Amparore D, Re C, Verep S, et al. What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group World J Urol, 2026.PMID 42373875
  5. [5]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
  6. [6]Miranda M, Ferreira C, Fernandes M, Lopes F, et al. Hereditary renal cell carcinoma surveillance protocols: a review of the literature and proposed recommendations Fam Cancer, 2026.PMID 41518461
  7. [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
  8. [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922